Cocrystal to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor

 

• Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuations
• Enrollment to be extended due to low influenza infection among challenged participants; virology results are uninterpretable

https://www.globenewswire.com/news-release/2024/12/31/3003109/0/en/Cocrystal-Pharma-to-Extend-Phase-2a-Influenza-Challenge-Study-with-Oral-PB2-inhibitor-CC-42344.html